There are currently 187 clinical trials in Tulsa, Oklahoma looking for participants to engage in research studies. Trials are conducted at various facilities, including Oklahoma Cancer Specialists and Research Institute-Tulsa, Natalie Warren Bryant Cancer Center at St. Francis Hospital, GSK Investigational Site and Natalie Warren Bryant Cancer Center at Saint Francis. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Oklahoma Study of Native American Pain Risk III: Stress and Resilience
NCT05723081
Recruiting
The goal of this observational study is to learn about the relationship between environmental structural racism and discrimination and chronic pain risk in Native American adults. The main questions it aims to answer are: 1. How does environmental structural racism and discrimination affect chronic pain-promoting mechanisms in Native Americans? 2. What psychosocial factors buffer the negative effects of environmental structural racism and discrimination on chronic pain-promoting mechanisms?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: University of Oklahoma - Schusterman Center, Tulsa, Oklahoma
Conditions: Discrimination, Racial, Stress Physiology, Pain
Register for Updates
Semaglutide Therapy for Alcohol Reduction - Tulsa
NCT05891587
Recruiting
The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: OSU Biomedical Imaging Center, Tulsa, Oklahoma
Conditions: Alcohol Use Disorder
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Cancer Treatment Centers of America, Tulsa, Oklahoma +1 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
NCT04636814
Recruiting
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/11/2025
Locations: Chiesi Clinical Trial - Site 840692, Tulsa, Oklahoma
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION
NCT04724447
Recruiting
This study aims to determine whether treatment of CMV positive (CMV+) individuals with major depressive disorder (MDD) with valganciclovir (VGCV) alters neural circuitry, reduces inflammation, and improves depressive behavior and symptoms to a greater extent than placebo. In this double-blind, randomized placebo-controlled, parallel group trial, 24 individuals with a Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) scale score ≥ 14 will be enrolled to participate in an 8-week t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Major Depressive Disorder
Register for Updates
Neural Response to Inflammatory Challenge in Major Depressive Disorder
NCT04751331
Recruiting
This is a parallel group, double-blinded, placebo-controlled study. Participants with MDD (n=90) and HC (n=90) will be randomly assigned (2:1) to receive either lipopolysaccharide (LPS) (0.8ng/kg of body weight) or placebo (same volume of 0.9% saline) administered as an intravenous bolus. This will yield the following groups: MDD-LPS (n=60), MDD-Placebo (n=30), HC-LPS (n=60), HC-placebo (n=30). There are three main aims: to identify immune pathways and neural circuits that respond differently t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Major Depressive Disorder
Register for Updates
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
NCT06263660
Recruiting
This study aims to determine whether a keto-like supplement relative to placebo results in functional brain changes during fMRI tasks evaluating positive and negative valence in individuals with moderate to severe depression. In this double-blind randomized placebo-controlled trial, 75 individuals with a Patient Health Questionnaire (PHQ-9) scale score ≥ 10 (MDD) will be enrolled to participate in an 8-week treatment study to obtain 60 completers. Participants will be randomized with a 1-1 ratio... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Depression
Register for Updates
Amplatzer Amulet LAAO Vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Oklahoma Heart Institute at Utica, Tulsa, Oklahoma
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
ctDNA Assay in Patients With Resectable Pancreatic Cancer
NCT05052671
Recruiting
The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may provide preliminary evidence that helps improve future patient care through targeted diagnostics, prognosis, and/or treatment.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/21/2025
Locations: Stephenson Cancer Center- Tulsa, Tulsa, Oklahoma
Conditions: Pancreas Cancer
Register for Updates
Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
NCT06153420
Recruiting
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo. * To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo Participants will attend the foll... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Options Health Research LLC, Tulsa, Oklahoma
Conditions: Irritable Bowel Syndrome With Diarrhea
Register for Updates
Beta-Adrenergic Modulation of Drug Cue Reactivity
NCT05587361
Recruiting
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
02/18/2025
Locations: Hardesty Center for Clinical Research and Neuroscience, Tulsa, Oklahoma
Conditions: Tobacco Use Disorder, Nicotine Dependence, Cigarette Smoking
Register for Updates
BostonGene and Exigent Genomic INsight Study
NCT06272864
Recruiting
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma
Conditions: Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
Register for Updates